Global Acquired Hemophilia Treatment Market Size and Forecast ... - Chatfield News-Record
CHGCY Stock | USD 21.63 0.80 3.84% |
Slightly above 55% of Chugai Pharmaceutical's investors are presently thinking to get in. The analysis of overall sentiment of trading Chugai Pharmaceutical Co pink sheet suggests that some investors are interested at this time. Chugai Pharmaceutical's investing sentiment can be driven by a variety of factors including economic data, Chugai Pharmaceutical's earnings reports, geopolitical events, and overall market trends.
Chugai |
Global Acquired Hemophilia Treatment Market Size and Forecast ... Chatfield News-Record
Read at news.google.com
Chugai Pharmaceutical Fundamental Analysis
We analyze Chugai Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chugai Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chugai Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Chugai Pharmaceutical is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Chugai Pharmaceutical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Chugai Pharmaceutical pink sheet to make a market-neutral strategy. Peer analysis of Chugai Pharmaceutical could also be used in its relative valuation, which is a method of valuing Chugai Pharmaceutical by comparing valuation metrics with similar companies.
Peers
Chugai Pharmaceutical Related Equities
ALPMF | Astellas Pharma | 9.50 | ||||
MRK | Merck | 1.48 | ||||
BAYZF | Bayer AG | 1.31 | ||||
AZN | AstraZeneca PLC | 1.27 | ||||
GILD | Gilead Sciences | 1.16 | ||||
NVS | Novartis | 1.02 | ||||
SNY | Sanofi ADR | 0.91 | ||||
GSK | GlaxoSmithKline PLC | 0.91 | ||||
BMY | Bristol Myers | 0.90 | ||||
RHHBY | Roche Holding | 0.90 | ||||
JNJ | Johnson Johnson | 0.57 | ||||
PFE | Pfizer | 0.23 | ||||
BMYMP | Bristol-Myers Squibb | 0.00 | ||||
SCLX | Scilex Holding | 4.69 |
Additional Tools for Chugai Pink Sheet Analysis
When running Chugai Pharmaceutical's price analysis, check to measure Chugai Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chugai Pharmaceutical is operating at the current time. Most of Chugai Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Chugai Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chugai Pharmaceutical's price. Additionally, you may evaluate how the addition of Chugai Pharmaceutical to your portfolios can decrease your overall portfolio volatility.